A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Relatlimab (Primary) ; Ipilimumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms FRACTION-RCC
- Sponsors Bristol-Myers Squibb
- 16 Jan 2018 Planned number of patients changed from 715 to 300.
- 30 Jun 2017 Planned number of patients changed from 650 to 200.
- 07 Feb 2017 Status changed from not yet recruiting to recruiting.